Logo
Logo

About Moxifloxacin Hydrochloride (Anhydrous) API

Product
  • Therapeutic Category抗感染

  • API Technology

    Synthetic

  • Dose Form

    Oral Solids, Injectable, Opthalmic

  • Dr Reddy's Development Status

    Available (Commercial)

  • Available Regulatory Filing

    USDMF, CEP Submitted, Brazil DMF, Canada DMF, Korea DMF, Russia DMF, Egypt DMF

作用机制

The bactericidal action of moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.

适应症

AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: 

  • Community Acquired Pneumonia
  • Skin and Skin Structure Infections: Uncomplicated and Complicated
  • Complicated Intra-Abdominal Infections
  • Plague
  • Acute Bacterial Sinusitis
  • Acute Bacterial Exacerbation of Chronic Bronchitis 

To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria VIGAMOX® solution is a topical fluoroquinolone antiinfective indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: 

  • Corynebacterium species*
  • Micrococcus luteus*
  • Staphylococcus aureus
  • Staphylococcus epidermidis
  • Staphylococcus haemolyticus
  • Staphylococcus hominis
  • Staphylococcus warneri*
  • Streptococcus pneumoniae
  • Streptococcus viridans group
  • Acinetobacter lwoffii*
  • Haemophilus influenzae
  • Haemophilus parainfluenzae*
  • Chlamydia trachomatis

Dr. Reddy's的专长

Dr. Reddy's总部位于印度海得拉巴,是全球领先的活性药物成分(API)供应商之一。 Dr. Reddy's的API业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国和新兴市场的制药公司的首选合作伙伴。

Dr. Reddy's博士的API业务在过去30多年来在开发和制造复杂API(如类固醇,多肽,复杂长链分子和高效API(HPAPI /肿瘤药物))方面所建立的深厚技术优势中茁壮成长。 我们在知识产权和法规事务方面的实力可以帮助我们始终如一地达到并超越监管标准,从而为这一专业知识提供补充。 Dr. Reddy's博士 盐酸莫西沙星无水合物 API是研发,知识产权和监管方面广泛专业知识的结果。

帮助我们的客户率先进入市场的关键组成部分是响应式供应链。 我们通过确保所有设施都高效运行并达到最新的质量,安全和生产率标准来实现这一目标。 业务和工厂之间的强大互联可以快速响应动态的市场变化,从而避免短缺并满足需求的突然激增。

RFQ Form

Phone

FAQs

What is MOXIFLOXACIN API used to treat?
  • It is an anti infective used to treat Pneumonia, Skin Infections, Plague Bacterial Sinusitis

What are the dosage strengths available for MOXIFLOXACIN API?
  • Available in Solution (IV), Tablet (Oral) - Sol - 400MG/250ML (1.6MG/ML). Tablet - 400MG base.

What are offerings of Dr. Reddy's for MOXIFLOXACIN API?
  • We offer an Anhydrous form

What is the process available for ordering MOXIFLOXACIN API?
Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.